Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cyclin-dependent kinases (CDKs) are crucial in cell regulation and cancer.
• CDK4 inhibitors are approved for breast cancer, driving interest in targeting other CDKs.
• Developing selective CDK inhibitors is challenging due to conserved ATP-binding sites.

Purpose of the Study:

• To review literature on targeting protein-protein interactions (PPI) involving CDKs 2, 4, 5, and 9.
• To explore PPI targeting as a strategy for achieving greater drug selectivity.
• To identify promising lead molecules for CDK-targeted therapies.

Main Methods:

• Literature review focused on studies targeting CDK-involving PPI.
• Analysis of challenges and opportunities in targeting these interactions.
• Identification and summary of promising lead compounds.

Main Results:

• Promising lead molecules targeting specific CDKs have been identified through PPI inhibition strategies.
• Protein-protein interactions offer a less conserved target compared to ATP-binding sites, aiding selectivity.
• No lead molecules have yet achieved FDA approval.

Conclusions:

• Targeting CDK-mediated PPI is a viable strategy for developing selective anti-cancer drugs.
• The reviewed studies provide a foundation for future development of PPI inhibitors for CDKs.
• Further research is needed to advance lead molecules to clinical application.